NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









KBP Biosciences

KBP Biosciences

Private
SingaporeHealthcare & Life Scienceshttps://kbpbiosciences.com/

Last Round

M&A

Oct 16, 2023

Total Funding Raised

$76M

Company Overview

KBP Biosciences is a clinical-stage biotechnology company that focuses on the research, development, and commercialization of small-molecule therapeutics for cardiorenal and infectious diseases.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticaldrug discoveryclinical-stage biotechsmall-molecule therapeuticsmineralocorticoid receptor antagonistMRAorgan protectionchronic kidney diseaseuncontrolled hypertensionclinical trialsdrug licensingbiotech pipelinepharma R&Daminomethylcycline antibiotic

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

KBP Biosciences Comps

Public and private peers based on sector, stage, and business model.

KBP Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

KBP Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
M&AOct 16, 2023
Series AJan 5, 2018

Key People

Founding team and executive leadership

tyler hendricks

CEO

Executive Team

James Fang

CFO

Executive Team

Julia Yang

Chief Operating Officer, Global Clinical Development, Global R D

Executive Team

KBP Biosciences Investors

Notable investors and investment history

Market signals

Structured signals derived from secondary market and firmographic data.

  • Feb 22, 2025

    Accused of failing to disclose crucial clinical trial results for ocedurenone.

KBP Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

KBP Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about KBP Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersSingapore
Employee Range44
Year Founded2011
Last FundingOct 16, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.